Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-04-2024 | Tacrolimus | Case report

Elasomeran/Tozinameran

Oral chronic graft-versus host disease

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Epstein JB, et al. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports. Case Reports in Oncology 16 : 1287-1292, No. 1, Dec 2023. Available from: URL: https://dx.doi.org/10.1159/000533821 Epstein JB, et al. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports. Case Reports in Oncology 16 : 1287-1292, No. 1, Dec 2023. Available from: URL: https://​dx.​doi.​org/​10.​1159/​000533821
Metadata
Title
Elasomeran/Tozinameran
Oral chronic graft-versus host disease
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57440-6

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Doxorubicin

Case report

Glucose

Case report

Iohexol

Case report

Pixantrone